Tower Research Capital LLC TRC Has $167,000 Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Tower Research Capital LLC TRC cut its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 18.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,972 shares of the company’s stock after selling 3,899 shares during the period. Tower Research Capital LLC TRC’s holdings in Ginkgo Bioworks were worth $167,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Erste Asset Management GmbH boosted its holdings in shares of Ginkgo Bioworks by 47.9% in the 4th quarter. Erste Asset Management GmbH now owns 739,332 shares of the company’s stock valued at $6,979,000 after buying an additional 239,332 shares during the last quarter. Forbes J M & Co. LLP lifted its stake in Ginkgo Bioworks by 461.4% in the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after acquiring an additional 576,732 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Ginkgo Bioworks by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 437,025 shares of the company’s stock valued at $4,294,000 after acquiring an additional 20,394 shares during the period. Monaco Asset Management SAM increased its stake in shares of Ginkgo Bioworks by 3.9% during the 4th quarter. Monaco Asset Management SAM now owns 384,664 shares of the company’s stock worth $3,777,000 after purchasing an additional 14,539 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. raised its holdings in shares of Ginkgo Bioworks by 33.1% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 361,750 shares of the company’s stock valued at $3,552,000 after purchasing an additional 90,000 shares during the period. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock opened at $6.45 on Wednesday. The stock has a 50-day simple moving average of $7.15 and a 200 day simple moving average of $9.10. The stock has a market capitalization of $374.49 million, a P/E ratio of -0.49 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $40.40.

Ginkgo Bioworks (NYSE:DNA) last posted its earnings results on Tuesday, May 6th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The business had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.